- Home
- BYAH vs BIAF Comparison
BYAH vs BIAF Comparison
Compare BYAH & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYAH | BIAF |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | China | United States |
| Employees | 41 | 57 |
| Industry | Package Goods/Cosmetics | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 4.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BYAH | BIAF |
|---|---|---|
| Price | $1.15 | $2.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 599.0K | 476.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.16 |
| 52 Week High | $2.77 | $13.50 |
Technical Indicators
Market Signals| Indicator | BYAH | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 78.12 |
| Support Level | $0.14 | $1.23 |
| Resistance Level | $2.77 | $3.58 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | -0.09 | 0.07 |
| Stochastic Oscillator | 7.65 | 62.00 |
Price Performance
Historical ComparisonAbout BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.